Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
01 juin 2016 07h30 HE
|
Assembly Biosciences, Inc.
NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV)...
Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
13 avr. 2016 07h00 HE
|
Assembly Biosciences, Inc.
—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties— —Planning to Start Phase 1...
Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
30 mars 2016 07h30 HE
|
Assembly Biosciences, Inc.
BARCELONA, Spain and NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for...
Assembly Biosciences Expands Senior Leadership Team
11 janv. 2016 07h30 HE
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus...
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
04 nov. 2015 16h01 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
02 nov. 2015 07h00 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase...
TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update
05 août 2015 16h01 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Provides Update on Hepatitis B Clinical Program
20 juil. 2015 16h02 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) a clinical-stage biopharmaceutical company focuses on discovering and developing novel small...
![Patient Advocate Foundation logo](/news-release/logo/315804/0/315804.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A30&size=2)
Hepatitis B Patients Benefit from New Co-Payment Assistance Fund
08 janv. 2015 09h38 HE
|
Patient Advocate Foundation
HAMPTON, Va., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Patient Advocate Foundation (PAF) is pleased to announce the addition of a new assistance fund to their Co-Pay Relief program dedicated to assisting...
![OnCore Biopharma, Inc.](/news-release/logo/310295/0/310295.jpg?lastModified=12%2F10%2F2016%2002%3A55%3A20&size=2)
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute
19 nov. 2014 07h00 HE
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...